Summary Interferon alpha (IFN-a) has a documented activity against malignant melanoma with a response rate of only approximately 20%. It would therefore be of considerable importance if patients likely to respond could be identified. The degree of mononuclear cell infiltration in primary tumours has been reported to correlate with a favourable prognosis. This investigation used monoclonal antibodies, anti-CD4, -CD8 and -CD 1 lc, to identify subsets of tumour-infiltrating mononuclear cells in fine needle aspirates to study whether the presence of such cells correlates with the therapeutic effect of IFN-a. Twenty-one patients with systemic and 20 with regional metastatic malignant melanoma were studied before initiation of IFN-a treatment. A statistically significant correlation (P<0.001) was found between the occurrence of CD4+ lymphocytes in fine needle aspirates and the therapeutic benefit of IFN-a in patients with systemic disease. Ten out of 11 with moderate to high numbers of infiltrating CD4+ lymphocytes achieved tumour regression. In contrast, among patients with low numbers of these cells in metastatic lesions, nine out of ten had progressive disease. Similar results were found in patients with regional disease.
Immune reactivity to malignant melanoma has been suggested by spontaneous regressions (Hurwitz, 1991) , the occurrence of antibodies of prognostic significance against melanoma-associated antigens (Jones et al., 1981) and specific cytotoxic lymphocytes (Abershold et al., 1991) . Conflicting results have, however, been reported on the prognostic significance of lymphocyte infiltration in primary malignant melanoma. Some studies found a significantly better prognosis if the primary lesions had a prominent infiltration of lymphocytes (Hansen and McCarten, 1974; Lasen and Grude, 1978) , whereas others found no such correlation (Balch et al., 1978) . Three studies also found a relation between tumour thickness and lymphocyte infiltration (Balch et al., 1978; Hansen and McCarten, 1974; Larsen and Grude, 1978) . Tumour-infiltrating lymphocytes were further studied by McGovern et al. (1981) , who found the infiltration at the base of the melanoma to be of prognostic significance in contrast to infiltration at the margins. McGovern et al. (1981) also found that the lymphocyte infiltration at the tumour base was reduced as tumour thickness increased. A reasonable strategy to treat malignant melanoma would therefore be to enhance the anti-tumour immune reactivity by immunomodulating substances, such as interferons and interleukin 2.
Interferon alpha (IFN-a) has a documented activity against metastatic malignant melanoma ( Legha, 1989) . Five to ten million units m-2 IFN-a three times weekly, at the cost of reasonable side-effects, seems to be an optimal dose range (Legha, 1989) . The treatment efficacy varies in different studies (Creagan et al., 1988; Legha, 1989) and the overall response rate (CR+PR) to IFN-cx alone is only about 20% (Creagan et al., 1988; Legha, 1989) . It would therefore be a considerable improvement if patients with a high probability of responding to this treatment could be identified using prognostic tests.
Besides having an anti-proliferative activity, the antitumour effect of IFN-oa can be caused by the modulation of tumour cells, e.g. increased expression of cell surface proteins such as MHC I and tumour-associated antigens, which are of importance for the immunological control of tumours. In addition, IFN-a modulates several immune functions (Balkwill, 1982) . There are still no firm data demonstrating which of the above-mentioned activities of IFN-ax is the most important for the anti-tumour activity or whether they all contribute.
As IFN-a modulates the activity of various cells in the immune system (Knop, 1990; Gresser, 1990 ) the therapeutic effect might depend on the immune status of the patients when IFN-a therapy is initiated.
The aim of the present investigation was to study whether the presence of subsets of tumour-infiltrating mononuclear cells identified by immunocytochemical staining of fine needle aspirates of metastatic malignant melanoma correlates with the response to IFN-a.
Materials and methods
Patient data This report describes 41 patients with metastatic malignant melanoma, 23 males and 18 females. Median age was 60 years (range 33-77 years) and Karnofsky performance status was 70 or more. Recurrences were cytologically verified by fine needle aspirates before start of treatment. Two groups of patients were studied, those with resectable regional disease and those with systemic disease. Twenty patients had metastases to regional lymph nodes, which in general were excised after 1 to 3 weeks of IFN-cx treatment. Twenty-one patients had systemic disease with the following metastatic sites: two cutaneous, five subcutaneous, 16 lymph nodes, eight pulmonary, four bone and 16 visceral (nine liver, one ovarian, one pancreatic, one vulvar, one adrenal gland and three spleen metastases). The number of metastatic sites were one in six patients, two in seven patients, three in four patients, four in one patient and five or more in three patients. Except for one patient who had had chemotherapy, no patient had previously been treated except for surgical removal of primary lesions or metastases. Patients with symptoms of brain metastases were not included in this study.
samples for measurements of creatinine, bilirubin, alkaline phosphatase, alanine aminotransferase, lactate dehydrogenase, alpha amylase, haemoglobin, white blood cells and thrombocytes.
Treatment schedule In a pilot study including 14 patients (six with regional disease and eight with systemic disease), IFN-ax was given subcutaneously (s.c.) 3 days weekly at a dose of 10 million IU in combination with cyclophosphamide at a dose of 300 mg m-2 administered as intravenous (i.v.) bolus every 3 weeks and seven of these patients were also treated with 50 mg of indomethacin three times daily. One patient was on cimetidine medication. This study was followed by the main study including 27 patients (14 with regional resectable disease and 13 with systemic disease). These patients were treated with IFN-x alone at the same dose and schedule as in the pilot study. In patients with regional resectable disease the treatment could only be given for 1 -3 weeks in order not to delay surgery. In patients with distant metastases treatment continued until tumour progression. One treatment cycle included 3 weeks of treatment followed by 1 week without treatment. Tumour response was evaluated in patients with regional resectable disease after 1 -3 weeks and in patients with systemic disease after one (clinically measurable disease) and three treatment cycles.
Monoclonal antibodies CD4 (Leu-3a, Becton-Dickinson) The antigen is present on the helper/inducer T subset and in low density on monocytes and in the cytoplasm of monocytes and macrophages. (Figure 1 ) showed considerable individual variation (Table I) . There was also a difference between metastases from patients with regional or systemic disease. Table II . Obviously there is a close correlation between anti-tumour effects and the presence of CD4+ lymphocytes. In the pilot study, five out of eight patients had moderate to high numbers of tumour-infiltrating CD4+ lymphocytes and all five achieved tumour regression. In contrast, the three patients with low numbers of these cells had progressive disease (P= 0.04). Similarly, in the main study, six out of 13 patients had moderate to high numbers of these cells infiltrating the metastases and five of these six patients responded to IFN-oc treatment, but only one out of seven with low numbers of CD4+ lymphocytes achieved tumour regression (P= 0.06). As no differences regarding tumour regression or occurrence of infiltrating inflammatory cells were found between the pilot study and the main study the patients of these studies were combined in a chi-square analysis (P<0.001, for the three sub-groups shown in Table  II ). Thus, moderate to high numbers of CD4+ lymphocytes Correlation between treatment efficacy and occurrence of tumour-infiltrating mononuclear cells in patients with regional metastases
In order not to delay surgery, patients with regional, resectable metastases were treated with IFN-cx for only [1] [2] [3] weeks. This is too short to allow an adequate determination of the treatment efficacy based on tumour size. Therefore, histopathological criteria used for tumour regression in primary melanoma were applied in the evaluation of these patients. Nine patients had marked histopathological regression (Figure 2a ) of the resected metastases and 11 patients had only minor or no regressive changes (Figure 2b ). Tumour areas with ongoing regression were generally permeated by CD4+ cells, CD8+ lymphocytes as well as CD11c+ cells (Figure 3a -c, but the occurrence of these cells was not used as a criterion of regression in this study). The average time to recurrence in patients with marked and minor or no histopathological regression was 17.2 (median 12, range 2-74+) and 12.8 (median 9, range 1-14) months respectively. The corresponding figures for overall survival for these groups were 31 (median 20, range 12-74+) and 20 (median 19, range 11-45+) months. The occurrence of inflammatory cells in relation to histopathological regression is shown in Table III . Obviously, there is a tendency to a correlation between antitumour effect and the presence of tumour-infiltrating CD4+ lymphocytes also in patients with regional metastases. In the pilot study three out of five patients and in the main study five out of nine patients with moderate to high numbers of CD4+ lymphocytes achieved marked histopathological regression. In contrast, five out of five patients in the main study with low numbers of CD4+ lymphocytes had no or only minor regressive changes in the metastases. When the pilot and the main studies were analysed together, seven out of ten patients with high numbers of tumour-infiltrating CD4+ lymphocytes showed marked histopathological regression in contrast to only one out of six patients with low numbers of these cells in the metastases (P= 0.077, X2-test for the three subgroups shown in Table III ). There was no correlation between the occurrence of CD8 + or CD 1 c+ cells and response to IFN-a treatment. (Hutchinson et al., 1981; Miescher et al., 1986; Vose and Moore, 1985) . The local immunosuppression was, however, found to be reversible (Hutchinson et al., 1981) . In some tumours, particularly in primary malignant melanomas, areas of tumour regression have been described (McGovern, 1975; Sondergaard and Hou-Jensen, 1985; Ronan et al., 1987; Kang et al., 1993) . This is in agreement with the presence of specific cytotoxic lymphocytes as has been described in several reports (Hutchinson et al., 1981; Rosenberg et al., 1986; Vose and Moore, 1985) . Based on these considerations it seems reasonable in the treatment of melanoma patients to try to overcome the immunosuppression or to enhance the immune reactivity to the tumours by immunomodulating substances. IFN-ax modulates various functions of the immune system (Balkwill, 1982) . The therapeutic effect might therefore depend on the presence of certain subsets of lymphocytes or macrophages infiltrating the tumours.
As T lymphocytes and macrophages are considered to be the most important cells for immunological control of malignant tumours, the presence of these subsets of cells in melanoma metastases has been analysed in the present study on the effect of IFN-oa. This study demonstrated that the presence of tumour-infiltrating CD4+ lymphocytes is of importance for the therapeutic effect of IFN-a. It can thus be concluded that one important anti-tumour effect of IFN-a is to enhance the immune reactivity towards the tumour.
CD4+ lymphocytes predominated over CD8+ lymphocytes and CD1 lc+ macrophages in most of our patients. The occurrence of tumour-infiltrating inflammatory cells varies in different studies. In a study by Tefany et al. (1991) , the ratio of CD4/CD8-positive cells infiltrating regressing tumours was increased compared with non-regressing tumours. Others found both CD4+ and CD8+ lymphocytes in melanoma (Kornstein et al., 1983; Poppema et al., 1983) . Ruiter et al. (1982) found variation in the predominance of CD8+ and CD4+ cells depending on tumour thickness. These conflicting results might to some extent be explained by the complex situation in these tumours, in which cytotoxic and immunosuppressor activities can be expected to be present simultaneously. The predominance of CD4+ cells found by us can be caused by either a preferential recruitment of these cells or impaired proliferative response and reduced clonogenic potential especially of tumour-infiltrating CD8+ cells (Miescher et al., 1988) . The CD4+ predominance might also be owing to stimulation by the cytokine RANTES which has been shown to be an important chemotactic factor able to stimulate migration and accumulation of CD4+ lymphocytes in solid tumours (Whiteside et al., 1992) . As a positive correlation with the therapeutic efficacy of IFN-a was found, it is reasonable to assume that CD4+ lymphocytes are of importance for the immune reactivity to the tumours. This is in good agreement with tumour regression in seven out of 11 patients treated with in vitro activated tumour infiltrating lymphocytes containing more than 80% CD4+ cells (Rosenberg et al., 1988) .
In order to evaluate properly a possible correlation between response to treatment and a parameter of potential predictive value, it is necessary to include all patients with measurable tumour regression in the analysis, that is at least also patients with minor regressions and mixed responses. It could be argued that also patients with disease stabilisation should be included in this group as the treatment actually had an anti-tumour activity as tumour progression was stopped. However, these patients are more difficult to identify accurately than those who achieve measurable regressions but do not fulfil the formal criteria for partial remission. If only patients with partial or complete remissions are regarded as responders, other patients with measurable regression will be erroneously allocated to the group of non-responders, which will obscure the results. This misinterpretation of data may be one reason why tests of predictive value for response to immunotherapy have only rarely been found.
The reason why short-lived, minor regressions do not continue and develop into partial or complete remissions is not clear, but the outcome of several months of immunotherapy is reasonably the end-result of a multistep process, e.g. initial immune-mediated lysis of tumour cells, selection of non-immunogenic tumour cell clones, down-regulation of the immune response to the tumour. Thus, in order not to misjudge the possibility of the immune system of these patients responding to immunotherapy, significant minor and mixed responses have to be included in the analyses.
Our study showed a close correlation between the occurrence of CD4+ lymphocytes and the therapeutic benefit of IFN-a. In patients with systemic disease, ten out of 11 of those with moderate or high infiltration of CD4+ lymphocytes in the tumours achieved tumour regression. In contrast, among patients with low infiltration of these cells, nine out of ten had progressive disease. Based on these results there seems to be a need for CD4+ lymphocytes infiltrating the tumours before start of treatment with IFN-a to make the treatment successful. Thus, the degree of infiltration of these cells seems to be a useful predictive test for choosing patients suitable for this therapy.
Different studies have been undertaken where adjuvant IFN-a treatment was given to high-risk patients showing a significant rise in relapse-free intervals (Kirkwood et al., 1996) . Perhaps also in this setting, patients most likely to benefit from IFN--a treatment can be selected based on the occurrence of CD4+ cells, thus increasing the cost-benefit of this treatment strategy considerably, in terms of both patient adverse reactions and health care costs.
